NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $15.00 -0.88 (-5.54%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$14.99 -0.01 (-0.07%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About 4D Molecular Therapeutics Stock (NASDAQ:FDMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FDMT alerts:Sign Up Key Stats Today's Range$14.68▼$15.9750-Day Range$9.61▼$16.7652-Week Range$6.96▼$16.93Volume1.47 million shsAverage Volume783,757 shsMarket Capitalization$828.60 millionP/E RatioN/ADividend YieldN/APrice Target$28.56Consensus RatingModerate Buy Company Overview 4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments. Its research and development programs have focused primarily on ophthalmic and pulmonary diseases. The company’s pipeline has included investigational gene therapies for retinal conditions such as wet age-related macular degeneration and diabetic macular edema, as well as programs intended to address diseases including cystic fibrosis and Fabry disease. Development programs and indications may change as clinical research progresses. Founded in 2013 and headquartered in Emeryville, California, 4D Molecular Therapeutics became a publicly traded company in 2020. The company was co-founded by David Kirn, M.D., who has served as its chief executive officer and has played a central role in its gene therapy research and corporate development. Its products remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More 4D Molecular Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreFDMT MarketRank™: 4D Molecular Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 297th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside Potential4D Molecular Therapeutics has a consensus price target of $28.56, representing about 90.4% upside from its current price of $15.00.Amount of Analyst Coverage4D Molecular Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 4D Molecular Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($4.07) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 4D Molecular Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.72% of the float of 4D Molecular Therapeutics has been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 8.15.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently decreased by 1.79%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.58 News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows2 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,743,197.00 in company stock.Percentage Held by Insiders7.90% of the stock of 4D Molecular Therapeutics is held by insiders.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 4D Molecular Therapeutics' insider trading history. Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FDMT Stock News HeadlinesInsider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 1,635 Shares of StockSeptember 23 at 5:22 AM | insidertrades.com4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 17, 2026 | seekingalpha.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)David Kirn Sells 58,333 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) StockSeptember 17, 2026 | insidertrades.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 7.3% on Analyst UpgradeSeptember 16, 2026 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Upgraded by Cantor FitzgeraldSeptember 16, 2026 | americanbankingnews.com4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.com4DMT Announces New Employment Inducement GrantsSeptember 11, 2026 | globenewswire.comSee More Headlines FDMT Stock Analysis - Frequently Asked Questions How have FDMT shares performed this year? 4D Molecular Therapeutics' stock was trading at $7.50 at the beginning of the year. Since then, FDMT stock has increased by 100.0% and is now trading at $15.00. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.02. The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative trailing twelve-month return on equity of 41.33%. When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $189 million in an IPO on Friday, December 11th 2020. The company issued 8,400,000 shares at $22.00-$23.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? Top institutional shareholders of 4D Molecular Therapeutics include Jupiter Topco LLC (10.99%), BlackRock Inc. (8.70%), Trails Edge Capital Partners LP (4.26%) and Bank of America Corp DE (2.14%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Ashoo Gupta, Scott Bizily and Robert Young Kim. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 4D Molecular Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings8/13/2026Today9/23/2026Investor Day 202610/21/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 FDMT's financial health is in the Green zone, according to TradeSmith. FDMT has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FDMT CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees196Year Founded2013Price Target and Rating Average Price Target for 4D Molecular Therapeutics$28.56 High Price Target$37.00 Low Price Target$17.00 Potential Upside/Downside+90.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.11 million Net Margins-194.74% Pretax Margin-194.74% Return on Equity-41.33% Return on Assets-35.90% Debt Debt-to-Equity Ratio0.05 Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$85.21 million Price / Sales9.72 Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book1.69Miscellaneous Outstanding Shares55,240,000Free Float50,880,000Market Cap$828.60 million OptionableOptionable Beta2.74 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:FDMT) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
